Pharmaceuticals 2010, 3(4), 1122-1138; doi:10.3390/ph3041122

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

1,2email and 2,* email
Received: 30 December 2009; in revised form: 12 March 2010 / Accepted: 9 April 2010 / Published: 15 April 2010
(This article belongs to the Special Issue Personalized Medicine)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced) factors may alter CYP2D6 enzyme activity directly affecting the concentrations of active tamoxifen metabolites. Several studies suggest that germline genetic variants in CYP2D6 influence the clinical outcomes of patients treated with adjuvant tamoxifen. Here, we review the existing data relating CYP2D6 genotypes to tamoxifen efficacy.
Keywords: tamoxifen; CYP2D6 genotyping; breast cancer
PDF Full-text Download PDF Full-Text [241 KB, uploaded 15 April 2010 09:11 CEST]

Export to BibTeX |

MDPI and ACS Style

Ferraldeschi, R.; Newman, W.G. The Impact of CYP2D6 Genotyping on Tamoxifen Treatment. Pharmaceuticals 2010, 3, 1122-1138.

AMA Style

Ferraldeschi R, Newman WG. The Impact of CYP2D6 Genotyping on Tamoxifen Treatment. Pharmaceuticals. 2010; 3(4):1122-1138.

Chicago/Turabian Style

Ferraldeschi, Roberta; Newman, William G. 2010. "The Impact of CYP2D6 Genotyping on Tamoxifen Treatment." Pharmaceuticals 3, no. 4: 1122-1138.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert